Haemostasis Is Forty-Three Per Cent of This Discipline and Fifty-Seven Per Cent of Its Growth

There is a sentence in almost every haematology pitch that is true and useless: the discipline is enormous by volume and small by value. The complete blood count is the most frequently ordered laboratory test in medicine and, per reportable result, one of the cheapest things a hospital buys. What that sentence hides is that the discipline stopped being one market some time ago.

In 2025 the field is USD 7,620 million, and it is two fields sharing a name. Haematology — analysers, reagents and controls for the differential, reticulocyte and body-fluid work, plus digital morphology — is USD 4,350 million, reaching USD 5,643 million by 2033 at 3.31%. Haemostasis — routine screening, D-dimer, anti-Xa, thrombophilia and factor assays, viscoelastic testing — is USD 3,270 million, reaching USD 4,988 million at 5.42%. Add them and you get the headline: USD 10,630 million and a 4.25% CAGR.

Nothing about that blend is wrong. Everything about it is uninformative.

The arithmetic of the inversion

The smaller field by value is the larger field by growth. Haemostasis supplies USD 1,718 million of the discipline’s USD 3,010 million increment — 57.08% of the growth from 42.91% of the base. A forecast that treats this as one market at 4.25% is treating a tug of war as a trend.

Volume and price run in opposite directions in the two halves

Haematology grows its test volume faster than haemostasis: 2,900 million reportable results to 4,020 million, a 4.17% CAGR, against 1,280 million to 1,740 million and 3.91%. And it grows its revenue more slowly. Which means the two fields are not diverging on demand. They are diverging on price.

That last row is the most misleading number in the report. Flat is not stable. Flat is two contrary movements cancelling, and a discipline whose average is flat while its halves run at −6.4% and +12.2% is a discipline whose average is about to stop describing anything.

The mechanism: a test that deleted its own annuity

The reason is not reimbursement policy operating on both halves equally. It is one clinical decision, taken over fifteen years, patient by patient.

An anticoagulated atrial-fibrillation patient on warfarin generates 13 to 26 PT/INR tests a year. The same patient on a direct oral anticoagulant generates, in routine monitoring, none. That is the single largest deletion of recurring test volume in in vitro diagnostics of the past fifteen years, and it happened inside a discipline whose installed base was justified by exactly that recurring workflow. Warfarin monitoring is why a coagulation analyser sat in every hospital laboratory; it is a textbook annuity — a fixed test, a fixed interval, a lifetime of repeats.

What replaced it is not volume. It is price. Anti-Xa assays, DOAC-calibrated measurements, thrombophilia workups, lupus anticoagulant testing, and viscoelastic testing in critical care and perioperative pathways each carry a multiple of a PT price and a fraction of the order frequency. A hospital that once ran four PTs a day on a patient now runs one anti-Xa when it matters, or a viscoelastic panel during surgery. Coagulation lost its annuity and bought a specialist’s fee. That trade is why the field’s revenue per result rises 12.21% while haematology’s falls 6.4% — and why the volume that left never comes back.

The concentration differs too, and that matters for who can price

Haematology is a monopoly. Sysmex’s disclosed haematology revenue is JPY 299,407 million for the year to March 2026 — USD 2,023 million at JPY 148/USD — or 46.5% of the USD 4,350 million field. Its own Integrated Report claims 54.6% of a USD 4,300 million field, which its disclosed revenue contradicts by 13.8%; both readings are given in the report, and the gap is carried as an uncertainty band rather than resolved.

Haemostasis is not a monopoly. On revenue, Werfen is the leader at an attributed USD 1,200 million, 36.7% of USD 3,270 million. Diagnostica Stago’s EUR 550 million is 19.02%. Sysmex’s disclosed hemostasis revenue of USD 489 million is 15.0%, and its own footnote concedes that its number-one claim “includes sales through alliances” — its instruments reach the market substantially under the Siemens Healthineers brand. Those attributions are ours, made on disclosed revenue, and labelled as such.

A field with one 46.5% owner is a field where a buyer knows precisely whom it is buying from. A field with three vendors between 15% and 37% is a field where a buyer can play them. That difference is visible in the price mechanism itself.

Two administered prices, landing on different halves

The American fee schedule cuts haematology. The preliminary CY 2027 Medicare Clinical Laboratory Fee Schedule takes code 85025 — the complete blood count, 36 million Medicare tests a year — from USD 7.77 to USD 6.89, an 11.3% reduction in the weighted median and 35% below its 2018 level. Haematology does not even have its own category in CMS’s results-by-category table, which names chemistry, molecular pathology, genomic sequencing, microbiology, proprietary laboratory analysis and immunology. The highest-volume test in American medicine is priced in an accounting bucket that does not name its field.

China cuts haemostasis. In January 2023 the Anhui provincial alliance ran the country’s first volume-based procurement for coagulation reagents: six coagulation items, 22 bidders, 16 selected, an average combined reduction of 40.16% and a maximum of 49.59%.

Two documents, two continents, two very different reduction sizes. Both are the same instrument applied to the half of the discipline where the buyer has least substitutability — which is the half that cannot escape by re-mixing its menu.

What would break the pattern

Two things, and both are observable.

The upside: if anti-Xa and DOAC monitoring acquire their own coding and coverage, haemostasis stops being a menu sold inside a routine-coagulation contract and becomes a reimbursed specialty line. The report’s upside case takes haemostasis to 6.5% and the discipline to USD 11,140 million at 4.86%.

The downside: if payers respond to the PT/INR decline by bundling routine haemostasis into a single episode payment, the field loses the per-line pricing that produced its entire price gain — and it loses it at the exact moment its volume is being tendered. The downside case is USD 10,180 million at 3.69%.

The band is 56 basis points either side of base, which is narrow, and that narrowness is the finding: this discipline’s forecast is not sensitive to technology adoption or to a product cycle. It is sensitive to whether two governments keep cutting administered prices, and to how quickly a specialist’s fee replaces a vanished annuity.

Method and disclosure

This analysis is built at a 70% secondary and 30% primary basis. The secondary layer is company disclosure read directly: Sysmex’s consolidated results and its net-sales-by-product table, Werfen’s annual review, Diagnostica Stago’s French filings and the ARCHIMED transaction announcement, Danaher and Abbott segment reporting, and Mindray’s annual results. The primary layer — 47 depth interviews across 13 markets, 29 open-ended interviews around tender cycles, a 176-respondent laboratory survey and four conferences — establishes mechanism only and carries no figure.

All market levels are ours. The discipline is constructed bottom-up from ten attributed pools totalling USD 6,684 million (87.72%) with a stated residual of USD 936 million (12.28%), and no published aggregate was used to set the level. FX basis JPY 148/USD and EUR 1.13/USD, matching the rest of this cluster. No third-party market-research material is cited anywhere in this piece.

Sources

• Sysmex Corporation — Summary of Consolidated Financial Results, FY ended 31 March 2026 (14 May 2026)
• Sysmex Corporation — Integrated Report 2025, field market size and share table
• Werfen — Annual Review 2025
• ARCHIMED — ARCHIMED Diagnostics acquires Stago (29 April 2026)
• Centers for Medicare & Medicaid Services — Preliminary CY 2027 Medicare CLFS Payment Rates (21 September 2026)
• People’s Daily, Anhui — Anhui completes China’s first coagulation and cardiac-marker IVD reagent volume-based procurement (20 January 2023)
• ISTH — guidance on direct oral anticoagulant monitoring and laboratory measurement
• Shenzhen Mindray Bio-Medical Electronics — 2025 annual results briefing (31 March 2026)

Companion reading

• Global Haematology and Coagulation Diagnostics Market, 2026–2033 — the full report this analysis is drawn from: two fields, two price paths, one tendered base.
• Global Clinical Chemistry and Urinalysis Market, 2026–2033 — the same fee-schedule reset cutting 387 chemistry codes by 16%, and the open-channel reagent market where the residual is 48.9%.
• Global Microbiology Diagnostics Market, 2026–2033 — the one discipline in the cluster where revenue per test rises because a culture is being rebilled as a panel.
• Global Infectious Disease Diagnostics Market, 2026–2033 — the application layer where blood-donor screening and the sepsis-driven blood culture workflow sit, and where volume runs ahead of revenue.

Related analysis

• Mindray Grew Share in a Market That Fell Twenty-Three Per Cent — the other half of this discipline’s price story: Anhui’s 40.16% average reduction on six coagulation items, the ceiling built from what hospitals had already paid, and why Mindray’s domestic revenue fell 22.97% while its international revenue rose 7.40%.
• The Mix Engine in Infectious Disease Diagnostics Stalls at Twenty-Six Per Cent of the Base — the mirror case in the same cluster, where price per test is falling on a base that is still resetting and the segment mix has a visible ceiling.